|
Dr. Goldstein has served as Chief Operating Officer since January 2006. Dr. Goldstein joined Maxygen in February 2003 as Senior Vice President, Clinical Development and Denmark Operations. Prior to joining Maxygen Dr. Goldstein held a number of senior executive positions in the pharmaceutical and biotechnology industry, including Chief Executive Officer of British Biotech from September 1998 to November 2002, and Senior Vice President, Worldwide Strategic Product Development at SmithKline Beecham (now GlaxoSmithKline) from April 1994 to September 1998. Before his tenure at SmithKline Beecham, Dr. Goldstein held a variety of senior level positions at Sandoz Inc. including Vice President, Clinical Research and Development at Sandoz Research Institute. Dr. Goldstein obtained his M.D. from the University of Aix-Marseille, France. | 